Mounjaro Vs Wegovy? Which is more effective?
Recently, two notable medications have surfaced in the field of diabetes management and weight loss in the UK: Mounjaro (Tirzepatide) and Wegovy (Semaglutide). Though both are classified as GLP-1 receptor agonists, they exhibit unique characteristics, mechanisms of action, and suitability for different patients. Wegovy (Semaglutide) and Mounjaro (Tirzepatide) are brand-name injections; while Wegovy is approved and prescribed for weight loss, Mounjaro was initially approved for treating type 2 diabetes but has since been officially authorised for weight loss and management by NICE in adults aged 18 and over in the UK, where it is prescribed specifically for weight loss purposes.
If you’re considering Wegovy or Mounjaro or want to learn more about weight loss injections, visit our Mounjaro Blog Page and Wegovy Blog Page for detailed information.
Additionally, you can contact SemaPen, part of the Phoenix Health bariatric group, a reputable NHS weight loss provider in the UK, for personalised advice to help you select the most suitable medication for you.
Is Mounjaro better than Wegovy?
While there has been no direct comparison between Wegovy and Mounjaro in clinical trials specifically for weight loss, their effects on individuals with type 2 diabetes have been evaluated in a review of trials. The review states that Mounjaro, when administered at its highest dosage of 15 milligrams (mg) weekly, resulted in more significant weight reduction compared to Wegovy, which is given at a peak dose of 2.4 mg weekly.
Furthermore, an additional review of trials analysed these medications’ impact on non-diabetic individuals found that patients taking Mounjaro (administered in dosages of either 10 mg or 15 mg weekly) showed greater weight loss than patients taking Wegovy (administered at 2.4 mg weekly).
It’s crucial to acknowledge that the findings from these trials and analyses might not directly correlate to your unique health circumstances. It’s recommended to consult with your healthcare provider to ascertain the suitability of Wegovy or Mounjaro for your specific needs.
Both medications have been shown to significantly reduce weight and enhance blood sugar levels in individuals, irrespective of their diabetic status. Nonetheless, it’s essential to bear in mind that individual results may vary depending on factors such as body mass index (BMI), pre-existing health conditions, and commitment to the weight loss regimen.
Note: To discover more about our weight loss programme, please visit the SemaPen weight loss programme page.
Comparing the Mechanisms of Action: Mounjaro vs. Wegovy
Mounjaro and Wegovy operate through different mechanisms in the body to influence weight and blood sugar levels. Mounjaro, as a dual GLP-1/GIP receptor agonist, works by increasing insulin production, lowering glucagon secretion, delaying stomach emptying, and enhancing feeling of fullness by activating specific brain regions. These combined actions result in better glycemic control, reduced appetite, and significant weight loss. In contrast, Wegovy relies solely on semaglutide, which primarily impacts the body through GLP-1 receptor activation. This leads to slower stomach emptying, increased satiety signals to the brain, and stable blood sugar levels, even with reduced caloric intake. While both medications aim to control blood sugar and reduce weight, Mounjaro’s dual approach offers a broader range of effects compared to Wegovy’s more focused action.
Is switching from Wegovy to Mounjaro easy?
It’s important not to use Wegovy and Mounjaro simultaneously, as doing so may lead to serious side effects without any added benefit. If you’re planning to switch, make sure to wait at least one week after your last Wegovy injection before taking your first Mounjaro dose.
If you’re already enrolled in SemaPen weight loss Programme and wish to switch, you can contact us, our team will help you to switch
If you’ve been prescribed elsewhere, we can assist you in switching to Mounjaro if it’s clinically suitable, or you can continue your Wegovy treatment with us at your current dose.
Visit the Manufacturer’s site for more information on the medications
The drugs have different manufacturers. Wegovy is made by the Danish pharmaceutical company, Novo Nordisk. Mounjaro is manufactured by the North American company, Eli Lilly.
How can SemaPen help with my weight loss goals?
SemaPen offers a comprehensive online weight loss programme to help you get started on your weight loss journey. As part of the Phoenix Health Group, which is the only private bariatric provider trusted by the NHS and has been helping people lose weight for more than 20 years with 300+ 5-star reviews on Trustpilot, SemaPen offers convenient online access to Mounjaro injections. Simply visit our SemaPen website and check your BMI eligibility. If you qualify, you can easily order your medication online with just a few clicks. You will also receive a sleek Withings® Body smart scale (worth £60) absolutely free, giving you and our support team real-time oversight of your progress. You’ll get exclusive access to personalised support from experts in obesity care. Our team of doctors, dietitians, nurses, and psychologists use SemaPen’s technology to ensure you stay on track for a great outcome.
Disclaimer: SemaPen web articles have made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed weight loss programme provider in the UK. You should always consult your healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all informations. The absence of any information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
References:
https://www.novonordisk.com/
https://www.lilly.com/
https://clinicaltrials.gov/study/NCT04184622?tab=results#results-overview
https://www.ema.europa.eu/en/documents/overview/Wegovy®-epar-medicine-overview_en.pdf